WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Norfolk Southern's earnings offer railroad chance to defend its strategy ahead of control voteNorfolk Southern's earnings offer railroad chance to defend its strategy ahead of control voteOklahoma prosecutors charge fifth member of antiNFL star Tyreek Hill hints he has TEN kids in new interview and insists he takes care of them allNootbaar, Gibson spark Cardinals to 5Is this the latest Nessie sighting? Hunter spots '18ftA look at the Gaza war protests that have emerged on US college campusesBiden picks up another big union endorsement, this one from building trades workersSouthwest Airlines flight attendants ratify a contract that will raise pay about 33% over 4 yearsNorfolk Southern's earnings offer railroad chance to defend its strategy ahead of control vote
2.6197s , 6500.0859375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Gazetteer news portal